<DOC>
	<DOCNO>NCT01594749</DOCNO>
	<brief_summary>This study aim demonstrate , give concomitantly 5-hydroxytryptamine 3 ( 5-HT3 ) antagonist corticosteroid , single 150 mg intravenous ( IV ) dose fosaprepitant give Day 1 superior control regimen 5-HT3 antagonist corticosteroid , prevent chemotherapy-induced nausea vomiting ( CINV ) associate moderately emetogenic chemotherapy ( MEC ) .</brief_summary>
	<brief_title>Efficacy Safety Fosaprepitant Dimeglumine Preventing Chemotherapy-Induced Nausea Vomiting ( MK-0517-031 )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prochlorperazine</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Thiethylperazine</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Has histologically cytologically confirm malignant disease Is naive moderately highly emetogenic chemotherapy Is schedule receive single IV dose one MEC agent Day 1 , except combination anthracycline cyclophosphamide Has predict life expectancy least 4 month , Karnofsky score least 60 indicate participant require occasional assistance , able care his/her need . Female childbearing potential demonstrates negative urine pregnancy test , agree remain abstinent use two acceptable form birth control least 14 day prior study , throughout study , least 1 month follow last dose study drug . Has vomit 24 hour prior treatment Day 1 Has symptomatic primary metastatic symptomatic central nervous system malignancy cause nausea and/or vomiting Is schedule receive chemotherapy agent classify highly emetogenic Has receive receive total body irradiation , radiation therapy abdomen , pelvis , head neck week prior Treatment Days 1 Day 6 Treatment Period Has illness history illness might confound study result pose unwarranted risk Known history QT interval prolongation Uses illicit drug abuse alcohol Mentally incapacitate significant emotional psychiatric disorder History hypersensitivity aprepitant , ondansetron dexamethasone Pregnant breastfeeding Has participate study aprepitant take nonapproved ( investigational ) drug within last 4 week Has concurrent condition , systemic fungal infection uncontrolled diabetes , precludes administration dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NK-1 Receptor Antagonist , CINV , Emesis , MEC</keyword>
</DOC>